Nov 4 2008
Fluxion Biosciences announced today an exclusive distribution agreement with East Sussex, UK-based Labtech International Ltd. Labtech will handle sales and service in the UK, Ireland and France of Fluxion's BioFlux(TM) research tools for live cell image analysis in drug discovery.
Labtech International Limited is a leading provider of innovative scientific products to researchers in the life science markets. Established in 1993, Labtech supplies their customers with a unique collection of innovative laboratory equipment, software and consumables. With a focus on understanding customer applications and requirements, Labtech invests heavily in providing first-class technical and service support as well as an efficient sales process.
“We selected Labtech as our distribution partner in the UK, Ireland and France because of their proven, unique sales methods,” explained Mark Atlas, director of sales for Fluxion. “Labtech has exceptional penetration of cell biology markets and their contacts are an ideal fit for our products.”
“We are enthusiastic about bringing Fluxion’s sophisticated systems to our customers in the European Union,” stated Brian Page, Ph.D., Labtech’s managing director. “The BioFlux system for live-cell imaging provides an exciting new tool for our customers and fits very well with our product portfolio and markets.”
The Fluxion BioFlux 200 system is ideal for live cell imaging in applications such as cell adhesion and microbial biofilm studies. BioFlux 200 incorporates Fluxion’s proprietary microfluidic design to deliver an automated, reproducible system for studying live cells and biofilms under controlled-shear conditions. The system simulates in vivo physiological conditions more closely and at higher throughput than other approaches.